NCT04117880View on ClinicalTrials.gov

A Phase 2 Open Label Extension Study in Participants With Nonsense Mutation Aniridia

PHASE2WithdrawnINTERVENTIONAL

0

Timeline

Start Date

December 31, 2018

Primary Completion Date

January 31, 2021

Study Completion Date

January 31, 2021

Conditions

Aniridia

Interventions

DRUG

Ataluren

Oral

Sponsors

Lead Sponsor

PTC Therapeutics

All Listed Sponsors

lead

PTC Therapeutics

INDUSTRY

NCT04117880 - A Phase 2 Open Label Extension Study in Participants With Nonsense Mutation Aniridia | Biotech Hunter | Biotech Hunter